Author Topic: Rituxan (rituximab)  (Read 61 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8134
  • MS diagnosed 1980
  • Location: Pacific Northwest
« Last Edit: January 07, 2019, 12:07:29 pm by agate »
MS Speaks--online for 12 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8134
  • MS diagnosed 1980
  • Location: Pacific Northwest
From JAMA Neurology (January 7, 2019)--this is a link to the entire article, entitled "Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis":


https://jamanetwork.com/journals/jamaneurology/fullarticle/2719699?guestAccessKey=17fb9684-d054-4bd4-a067-c9e3bb1b9462&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=010719

« Last Edit: January 07, 2019, 11:57:29 am by agate »
MS Speaks--online for 12 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8134
  • MS diagnosed 1980
  • Location: Pacific Northwest
This small study found that patients treated with rituximab before switching to glatiramer acetate (Copaxone) were more likely to show NEDA (no evidence of disease activity) than patients who received placebo before the change to Copaxone. From PubMed, January 13, 2019:


https://www.ncbi.nlm.nih.gov/pubmed/30635477


Apparently the patients received 2 infusions of Rituxan before starting daily Copaxone injections (from ClinicalTrials.gov Identifier: NCT01569451)[size=78%]:[/size]


Active Comparator: (Placebo and) Glatiramer Acetate
Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.


Experimental: Rituximab and Glatiramer Acetate (R-GA)
Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
« Last Edit: January 15, 2019, 01:49:23 pm by agate »
MS Speaks--online for 12 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
95 Views
Last post April 21, 2016, 05:17:20 pm
by agate
1 Replies
100 Views
Last post June 14, 2017, 10:35:24 am
by agate
0 Replies
46 Views
Last post May 17, 2017, 10:17:02 am
by agate
0 Replies
35 Views
Last post May 30, 2018, 12:19:55 pm
by agate
0 Replies
30 Views
Last post September 29, 2018, 11:36:07 am
by agate